<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606059</url>
  </required_header>
  <id_info>
    <org_study_id>DW0919-1003</org_study_id>
    <nct_id>NCT01606059</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of DW-0919 &amp; DW-0920 in Healthy Male Volunteers Under Fasting Condition</brief_title>
  <acronym>DW0919-1003</acronym>
  <official_title>A Randomized, Open Label, 2-treatment, 2-sequence, Cross-over Study to Compare the Safety and Pharmacokinetics of DW-0919 and DW-0920 After Single Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and pharmacokinetics of DW-0919 and DW-0920
      in healthy male volunteers under fasting condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of DW-0919(Acetaminophen, Tramadol)</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of DW-0919(Acetaminophen, Tramadol)</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of DW-0920(Acetaminophen, Tramadol)</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of DW-0920(Acetaminophen, Tramadol)</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>DW-0919</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DW-0920</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW-0920</intervention_name>
    <description>Dosage form: Extended release tablet Dosage: 2 tablets</description>
    <arm_group_label>DW-0920</arm_group_label>
    <other_name>Acetaminophen: 325mg</other_name>
    <other_name>Tramadol: 37.5mg</other_name>
    <other_name>Wontran ER tab.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW-0919</intervention_name>
    <description>Dosage form: Extended release tablet Dosage: 1 tablet</description>
    <arm_group_label>DW-0919</arm_group_label>
    <other_name>Acetaminophen: 650mg</other_name>
    <other_name>Tramadol: 75mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males aged 20 to 55 years at screening.

          -  No significant congenital/chronic disease.

          -  No symptoms in physical examination.

          -  Appropriate subjects as determined by past medical history, laboratory tests, serology
             and urinalysis.

          -  Be able to understand the objective, method of the study, the characteristics of
             investigational drug, and comply with the requirement of the study. Subject must
             provide written informed consent prior to study participation.

        Exclusion Criteria:

          -  History of Hyperreactivity with drug ingredients(acetaminophen, tramadol) or opioids.

          -  History or presence of liver, kidney, or nervous system disease, respiratory
             disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric
             or cognitive disorders.

          -  History of gastrointestinal disorders (bleeding, ulceration, hemorrhoids, piles) or
             disorders of absorption, distribution, metabolism, excretion.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>DaeJeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

